HIV-1 possesses an intrinsic genetic diversity and adaptive potential that poses a substantial barrier not only to the development of an effective vaccine, but also to a complete understanding of the interindividual and interpopulation variations in clinical course. In subSaharan Africa, home to ∼26.6 million HIV-infected persons (∼63% of global infections) [1, 2] , more information about the pathogenic and clinical consequences of HIV-1 subtypes is needed.
Three groups of HIV-1 are known to exist: major (M), outlier (O), and non-M and non-O (N) [3] [4] [5] .
Although there is clear evidence of the increased virulence of HIV-1, compared with that of HIV-2 [20, 21] , studies investigating intersubtype variation in disease progression have been equivocal. Studies conducted by Kanki et al. [14] among female sex-workers in Senegal and by Kaleebu et al. [22, 23] in cohorts in Uganda have shown significant variation between infecting subtypes, with respect to the speed of progression to AIDS or death. This pathogenic heterogeneity has also been suggested in cross-sectional correlations between disease stage and viral subtype [24] . Yet findings of Alaeus et al. [25] from a study of ethnic Swedes and Africans and results of studies of Ethiopian immigrants in Israel conducted by Galai et al. [26] have shown no significant variation in disease progression between HIV-1 subtypes in these untreated populations. We attempted to further elucidate the relationship between HIV-1 subtype and disease progression in a study population that included large numbers of infections with 3 major subtypes, including subtype C, the most prevalent subtype in the HIV pandemic.
METHODS

Patient population.
Samples analyzed in this study were obtained from women enrolled in the Trial of Vitamins in HIV-1 Progression and Transmission, a randomized, double-blind, multifactorial trial to assess the effect of supplementation with vitamins on various outcomes related to HIV-1 transmission and progression in Dar es Salaam, Tanzania [27] . HIV-1 serostatus was determined by means of ELISA with confirmatory Western blot test. Pregnant women with HIV infection at 12-27 weeks gestation were enrolled between April 1995 and July 1997, and they were followed up at monthly clinic visits that included assessment of symptoms, physical examination, and medical management [28] . Of the 1078 consenting seropositive mothers who were randomized to receive supplements or placebo, 428 had their HIV-1 subtype determined for this analysis, as part of a nested case-control study examining the relation of subtype to perinatal HIV-1 transmission [18] . Subtype was determined for all children with HIV-1 infection. Matching strata were determined by year of randomization and the time at which each child's samples were obtained, so that the interval over which transmission did or did not take place was similar for case patients and control patients. Within strata, control patients were randomly chosen, up to the number of case patients. A woman could be a control patient in one stratum and her child could be a case patient in a later stratum. Whole blood samples were collected at baseline (i.e., at randomization) and at subsequent clinic visits. Viral load, CD4
+ cell count, and other serological indicators were also determined. Demographic data were collected at baseline by an interviewer-administered questionnaire. Study design and recruitment, including laboratory and survey methods, have been outlined in detail elsewhere [29, 30] . Viral sequencing and classification. Frozen PBMC samples collected at enrollment were separated on a Ficoll density gradient and sent to the Harvard School of Public Health (Boston, MA) for viral sequencing. Nested PCR amplification was used for the C2-C5 envelope regions (env) and the 3 -p24/5 -p7 region of gag (appendix). Primers vpu157 (5 -GCAGAAGACAG-TGGCAATGA-3 ), vpu232 (5 -TGCTCCTTGGGATATTGA-TGA-3 ), p130 (5 -TTGATGCCCCAGACTGTGAGTT-3 ), and p131 (5 -AGCCAGGACTCTTGCCTGGAGCT-3 ) were used for the first PCR amplification of env, which was performed on 20 mL of crude cell extract. The product of this PCR was then amplified with nested primers Bstq2+ (5 -CCAATTCCTA-TACATTATTGTGC-3 ) and env1556 (5 -CCATAGTGCTTCC-TGCTGCTCCTAAGAACCCAA-3 ). Amplification cycles for both PCR reactions consisted of 39 cycles of 1 min at 94ЊC, 1 min at 52ЊC, and 3 min at 72ЊC and a final extension cycle of 10 min at 72ЊC. For the gag sequence, another 20 mL of cell extract was used for initial amplification with primers p108 (5 -GACTAGCGGAGGCTAGAAG-3 ) and p109 (5 -AGGGGTC-GTTGCCAAAGA-3 ). The nested PCR was then done using primers p91 (5'-CACCTATCCCAGTAGGAGAAATC-3 ) and p92 (5 -CCCTCCACATCTCCAACAGC-3 ). PCR conditions were similar for env amplification, but the extension at 72ЊC was done for 1 min. The 957 base pair env and the 493 base pair gag amplicons were gel purified and cloned into a plasmid vector. Bacterial colonies were screened for the presence of the insert using restriction enzyme analysis of plasmid DNA. Env and gag clones were sequenced in both directions by means of cycle sequencing with dye terminators (Applied Biosystems) [11] .
On the basis of the gag and env sequences obtained from each sample, an overall HIV-1 subtype classification was assigned to each mother on the basis of comparison with control sequences obtained from the Los Alamos National Laboratory Database [31] . These control sequences were aligned with our sample sequences using Clustal W software (European Bioinformatics Institute) [32] and then were subjected to neighborjoined phylogenetic analysis and the Kimura 2-parameter model for calculation of distances [33] . Intragenic recombinant viruses were detected among our samples using the Recombination Identification Program (RIP; Los Alamos National Laboratory) [34] . On the basis of these analyses, samples were classified as A, C, D, or recombinant. Detailed sample preparation, PCR amplification (including primer location and/or numbering), virus sequencing, and subtype classification have been described elsewhere [10, 11] .
Statistical analysis. [35] . The outcomes were analyzed in separate models.
Cox proportional hazards regression was employed (SAS software, version 8.0; SAS Institute) using viral subtype as the exposure of interest. Previous results [14, 22, 23] demonstrating subtype A to be associated with slower disease progression led us to select it as the reference against which the other subtypes were compared. Kaplan-Meier survival curves and the log-rank test were also used to examine the relationship between subtype and the progression endpoints. Analyses in which a CD4 + cell count of !200 cells/mm 3 was the outcome were used only for women whose baseline CD4 + cell count was at least 200 cells/ mm 3 . Women who were lost to follow-up were considered to be censored as of the last time we collected information regarding the outcome of interest.
Given the established risk factors associated with acquisition, transmission, and progression of HIV disease, including virus and host genetics, nutritional status, education, and socioeconomic status, we adjusted for all covariates that may confound the association between HIV-1 subtype and clinical disease progression. Baseline enrollment characteristics were compared among the viral subtypes using the Kruskal-Wallis test for continuous variables and the x 2 test or Fisher's exact test for categorical variables. Covariates were then entered into the model in a stepwise approach, with preference given to the categorical version of the variable to assess dose-response relationships. Significance was tested at each step on the basis of P values from likelihood-ratio tests, which determined inclusion in the final multivariate model. In the multivariate analyses, we used the missing indicator method to prevent loss of observations, because of missing data. In addition, because this study group differed from the main study group by several factors, including assignment to receive multivitamins, further analyses were done that included all variables for which differences occurred. ). These null results should be viewed cautiously, however, given that a substantive proportion (20.3%) of the subjects excluded from the analysis were left out because of the absence of a recorded CD4 + cell count rather than because they had a prevalent case (CD4 + count, !200 cells/mm 3 ) at baseline. Because of the uneven assignment of patients in this cohort to a multivitamin regimen as part of the main study, in addition to other differences between this study group and that of the larger primary study, assignment to a multivitamin regimen, as well as all variables by which this subgroup differed significantly from the overall study cohort, were included in separate multivariate models. In addition to the variables cited at the beginning of the Results section, transmission of HIV-1 to a woman's child was also included, because of the study design. These added variables did not appreciably change the results for any of the 3 outcomes for disease progression.
RESULTS
Enrollment characteristics.
DISCUSSION
This study demonstrates heterogeneity in the progression of HIV-1 infection on the basis of infecting subtype. Across endpoints, women with subtype D were more than twice as likely to progress to the endpoint as were women with subtype A. The fact that subtypes A and D have been cocirculating in the Tanzanian population since the late 1980s argues against the belief that HIV-1 subtype D entered first into the Tanzanian population and that women with subtype D were infected earlier than were women with HIV-1 subtype A. Although it appears that subtype C and intersubtype recombinant viruses entered Tanzania later than subtype D or subtype A [10], we did not find significant differences in disease progression between mothers infected with subtype A and subtype C or with intersubtype recombinant viruses. Adjustment for potential confounders only strengthened the associations, and the results were also consistent when variables by which the study group differed from the original study cohort were included in the models. Subtype C and the recombinant viruses did not differ significantly from subtype A for any endpoint, and, thus, the association of these viruses with disease progression, in relation to the other subtypes, remains equivocal. This study does, however, support previous findings of a significant difference in the pathogenicity of HIV-1 between patients infected with subtype D and patients infected with subtype A [22, 23] , and to our knowledge it is the first study of its kind to demonstrate this strong association across 3 different indicators of disease progression.
Our study has several limitations. Because it was conducted within the larger Trial of Vitamins in HIV-1 Progression and Transmission [27] , which was composed initially of pregnant HIV-infected mothers, it is not representative of the larger population, including nonpregnant women, men, and children, even though the women were not pregnant for most of the person-time of the follow-up period.
The major limitation of our study is the unknown date of seroconversion for the enrolled subjects. Therefore, rates of progression for the 3 outcomes were not calculated from the time of infection, but rather from the time of detection of HIV seropositivity and randomization into the trial. Duration of infection may have been partially controlled for in our multivariate models by adjusting for baseline CD4 + cell count and baseline viral load, which provided a rough proxy for immunological and virological stage of infection. Taken together, these indicators have been shown to be strong predictors of disease progression [36] [37] [38] [39] . Even without knowing dates of seroconversion, we do not feel that this unknown is likely to have introduced a substantial bias in our analyses, because there was no statistical evidence for significant variability in CD4 + cell count or viral load across the 4 subtypes at baseline. However, the amount of missing data for baseline viral load is substantial (data for 166 subjects [38.8%]) , and this may have reduced our ability to control completely for this factor. Despite these drawbacks, our study is the only one of its kind to account for baseline viral load in a prospective analysis of disease progression.
There were limitations in the ascertainment of CD4 + cell count and clinical stage that could explain the relatively null and nonsignificant results for subtype C and recombinant viruses, particularly in the multivariate analyses. CD4 + cell counts were determined during follow-up visits, but there was a modest number of subjects (74 [17.3%] ) ineligible for analysis because of a missing or a low baseline CD4 + count. Although the number of excluded subjects did not differ across subtype exposure categories, it cannot be discounted that there may have been inherent characteristics related to the pace of disease progression and CD4 + cell counts among the ineligible subjects that differed from those of included subjects.
Disease stage was assigned using the WHO algorithm, almost solely on the basis of clinical data obtained during follow-up examinations. Loss to follow-up for staging was more likely to occur as subjects became more ill and approached end-stage disease, thus many of the available data for staging were censored. Further questioning of family and community members was used to ascertain time and cause of death for subjects who did not continue with their clinic visits, but because there were no clinical data available from the time of their last visit to the time of death, assessing stage in these patients proved difficult. Thus, the censoring time for the death or stage 4 endpoint may have been shorter for some patients who died but were lost to clinical follow-up, assuming that many patients reached stage 4 of illness before death.
Relative to prior studies, there were advantages to our cohort, particularly the large sample size ( ) and the multiple n p 428 subtype composition (A, C, D, and recombinant viruses). No other prospective study of HIV-1 disease progression has had this level of subtype diversity in concert with a sufficiently large sample size. Unlike previous population-based studies of subtype and disease progression, we used both gag and env sequences to determine the overall subtype classification. We have done extensive genetic characterization of viral genomes, including nucleotide sequencing of full-length proviral DNA and sequencing multiple gag and env clones from independent PCR reactions. These genetic analyses indicated that the presence of discordant gag and env subtypes is the result of the existence of an intersubtype recombinant genome, not the existence of a dual infection [40] [41] [42] .
The results of this study suggest that subtype D may be more pathogenic than subtypes A and C and recombinant viruses. One possible explanation of this disparity is the differential use of coreceptors for entry into the cell by each of the subtypes in our cohort. HIV-1 subtype A-and to an even greater extent, subtype C-seem to favor the CCR5 receptor for viral entry along the entire spectrum of disease progression. This correlates to a nonsyncytium inducing macrophage-tropic phenotype of HIV-1 and is associated with slower viral growth and replication [16, 17, 43] . Subtype D, however, presents a simultaneous dual tropism for CCR5 and/or macrophages-in addition to fastprogressing, syncytium-forming CXCR4 receptors primarily observed in T cells-throughout the course of infection [13, 17, [44] [45] [46] [47] . This means that subtype D could theoretically, infect more cells per unit time, replicating faster than the other subtypes. Although it is only one part of the HIV virus replication cycle, this increased coreceptor attachment could support the more-rapid progression of patients in our study infected with this strain of HIV-1, ceteris paribus. Because most of the recombinant viruses observed in our cohort are non-CRF mosaic viruses, we cannot demonstrate the level or type of coreceptor use for this classification. But, given that subjects infected with recombinants progressed faster to death than patients infected with subtype A, we can posit that these mosaic viruses probably may not be solely macrophage-and/or CCR5-tropic.
Categorization by clade or subtype provides a convenient classification of HIV-1 subtypes based on evolutionary differences. However, genetic changes that influence virus phenotype represent only a subset of those alleles that determine phylogenetic subtype. Because of this, it is possible that the same associations with virulence may not be present with subtypes that evolved independently in other geographical regions.
This study examines multiple virus subtypes and disease progression in a treatment-naive population. Future studies of intersubtype variation in clinical course and drug resistance among populations receiving antiretroviral therapy is necessary. There is also a need for continuous prospective monitoring of HIV-1 loads as a measurement of progression, because it is another accurate prognostic indicator of disease stage and clinical course, in addition to CD4 + cell count [35] . Understanding the causes of heterogeneity in disease progression of HIV-1 infection between individuals and populations is still needed and will have implications on the development of new effective diagnostics, therapies, and preventive vaccines.
